Biotech entity
pharma is the sole category represented across all 3 tracked stories. Each story carries 2 original sources on average, compared with 3.9 for the broader beat in this window. Advanced Drug Delivery Technologies is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories.
Last mentioned: Mar 11, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 3 tracked stories. Each story carries 2 original sources on average, compared with 3.9 for the broader beat in this window. Advanced Drug Delivery Technologies is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. The 145-day window averages about 0.1 stories each week. At 6.7, the average consequence score sits above the same-window beat average of 6.3. DelveInsight Business Research LLP appears in 3 tracked Biotech stories published from March 5, 2026 through July 27, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 467 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering DelveInsight Business Research LLP. Shared-story counts are live from our verified record — not editorial picks.
A new DelveInsight forecast projects a 47% CAGR for the Alport syndrome market through 2036, fueled by a pipeline of gene and targeted therapies. The report highlights ELX-02 from Eloxx as a potential first-mover gene therapy with an 8-week dosing interval, while big pharma players like Bayer and Novartis advance competitors.
Source: prnewswire.com · finanznachrichten.de
The global minimally invasive surgical devices market is projected to grow at a 7% CAGR through 2034, driven by technological advancements and a shift toward outpatient care. This growth reflects a broader healthcare transition prioritizing reduced recovery times and improved patient outcomes.
The global nanomedicine market is projected to exceed $550 billion by 2034, fueled by the rapid adoption of advanced drug delivery systems. This growth marks a significant shift toward precision therapeutics, particularly in oncology and neurology, as nanoparticles become the standard for targeted treatment.
DelveInsight Business Research LLP is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
